SCHEMBL1792306

SCHEMBL1792306

CC(C)N(CCCCNCc1ccc(S(=O)(=O)N(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.50
TAAR1 Q96RJ0 5/20 0.40
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
CNR2 P34972 3/20 0.35
BACE1 P56817 1/20 0.34
SCN8A Q9UQD0 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA9 Q16790 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
AVPR1B P47901 1/20 0.33
CNR1 P21554 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798997 0.89 CXCR4 (0.48) CXCR4TAAR1CYP2D6TSHRLMNA
SCHEMBL1793549 0.87 CXCR4 (0.67) CXCR4TAAR1HCRTR1HCRTR2CNR2
SCHEMBL1802371 0.79 CXCR4 (0.64) CXCR4TAAR1CYP2D6TSHRLMNA
SCHEMBL1796506 0.77 CXCR4 (0.64) CXCR4TAAR1CNR2CYP2D6TSHR
SCHEMBL2695437 0.71 HCRTR1 (0.44) TAAR1HCRTR1HCRTR2CNR2CYP2D6
SCHEMBL1795129 0.70 CXCR4 (0.53) CXCR4TAAR1CA12CA2CA9
SCHEMBL1204806 0.70 CXCR4 (0.72) CXCR4TAAR1CYP2D6TSHRLMNA
SCHEMBL2693687 0.69 CXCR4 (0.37) CXCR4TAAR1HCRTR1HCRTR2CNR2
SCHEMBL2693691 0.69 CXCR4 (0.37) CXCR4TAAR1HCRTR1HCRTR2CNR2
SCHEMBL4921625 0.68 NAMPT (0.49) CXCR4TAAR1HCRTR1HCRTR2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP disclosed
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CCR5, CXCL12 CXCR4 1/4885TAAR1 903/4885HCRTR1 750/4885
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885TAAR1 1001/4885HCRTR1 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.